Paradoxical upregulation of tumor suppressor protein p53 in serum-stimulated vascular smooth muscle cells: A novel negative-feedback regulatory mechanism

Circulation

Volumn 108, Issue 4, 2003, Pages 464-471

  Mnjoyan, Zakar H ^a   Dutta, Ranjan ^a   Zhang, Di ^a   Teng, Ba Bie ^a   Fujise, Ken ^a  

^a NONE

Author keywords

Angioplasty; Apoptosis; Atherosclerosis; Growth substances; Restenosis

Indexed keywords

PROTEIN BAX; PROTEIN P21; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANGIOPLASTY; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL CYCLE; CELL PROLIFERATION; CELL STIMULATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; NICK END LABELING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOOD PROTEINS; BROMODEOXYURIDINE; CAUSALITY; CELL COUNT; CELL DIVISION; CELLS, CULTURED; CONSENSUS SEQUENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEEDBACK, BIOCHEMICAL; GENE EXPRESSION; HUMANS; IN SITU NICK-END LABELING; MUSCLE, SMOOTH, VASCULAR; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; S PHASE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0042164553     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000080339.49212.49     Document Type: Article

References (40)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
2. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
3. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 1994;266:1376-1380.
4. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997;1:3-11.
5. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
6. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053-1058.
7. Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature. 1997;389:300-305.
8. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-1238.
9. Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA. 1982;247:2692-2694.
10. Hainaut P, Soussi T, Shomer B, et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 1997;25:151-157.
11. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.
12. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E: evaluation of lesional development and progression. Arterioscler Thromb. 1994;14:141-147.
13. Guevara NV, Kim HS, Antonova EI, et al. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999;5:335-339.
14. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994;265:391-394.
15. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-630.
16. Wei GL, Krasinski K, Kearney M, et al. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 1997;80:418-426.
17. Gong L, Kamitani T, Fujise K, et al. Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9. J Biol Chem. 1997;272:28198-28201.
18. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 1996;6:995-1001.
19. Fujise K, Zhang D, Liu J, et al. Regulation of apoptosis and cell cycle progression by MCL1: differential role of proliferating cell nuclear antigen. J Biol Chem. 2000;275:39458-39465.
20. Li F, Zhang D, Fujise K. Characterization of fortilin, a novel anti-apoptotic protein. J Biol Chem. 2001;276:47542-47549.
21. Zhang D, Li F, Weidner D, et al. Physical and functional interaction between MCL1 and fortilin: the potential role of MCL1 as a fortilin chaperone. J Biol Chem. 2002;277:37430-37438.
22. Vojtesek B, Bartek J, Midgley CA, et al. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992;151:237-244.
23. Park JS, Boyer S, Mitchell K, et al. Expression of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21(Cip-1/WAF1/MDA6). J Biol Chem. 2000;275:18-28.
24. Wu FY, Tang QQ, Chen H, et al. Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha. Proc Natl Acad Sci U S A. 2002;99:10683-10688.
25. Ahmed MM, Alcock RA, Chendil D, et al. Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2. J Biol Chem. 2002;277:2234-2246.
26. Ruhl M, Sahin E, Johannsen M, et al. Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis via downregulation of Bax. J Biol Chem. 1999;274:34361-34368.
27. Ciriolo MR, De Martino A, Lafavia E, et al. Cu,Zn-superoxide dismutase-dependent apoptosis induced by nitric oxide in neuronal cells. J Biol Chem. 2000;275:5065-5072.
28. Schreiber E, Matthias P, Muller MM, et al. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 1989;17:6419.
29. Cain C, Miller S, Ahn J, et al. The N terminus of p53 regulates its dissociation from DNA. J Biol Chem. 2000;275:39944-39953.
30. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol. 1999;162:2095-2102.
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
32. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature. 1994;372:100-103.
33. Reich NC, Levine AJ. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature. 1984;308:199-201.
34. Aoki M, Morishita R, Matsushita H, et al. Serum deprivation-induced apoptosis accompanied by up-regulation of p53 and bax in human aortic vascular smooth muscle cells. Heart Vessels. 1997;(suppl 12):71-75.
35. Aoki M, Morishita R, Matsushita H, et al. Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells: potential role of p53 in regulation of vascular smooth muscle cell growth. Hypertension. 1999;34:192-200.
36. Kearney M, Pieczek A, Haley L, et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 1997;95:1998-2002.
37. Sionov RV, Haupt Y. The cellular response to p53: the decision between life and death. Oncogene. 1999;18:6145-6157.
38. Scheinman M, Ascher E, Levi GS, et al. p53 gene transfer to the injured rat carotid artery decreases neointimal formation. J Vasc Surg. 1999;29:360-369.
39. Scheinman M, Ascher E, Kallakuri S, et al. P53 gene transfer to the injured rat carotid artery promotes apoptosis. Surgery. 1999;126:863-868.
40. Yonemitsu Y, Kaneda Y, Tanaka S, et al. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Rev. 1998;82:147-156.